|
AU2015247817C1
(en)
*
|
2014-04-14 |
2022-02-10 |
Arvinas Operations, Inc. |
Imide-based modulators of proteolysis and associated methods of use
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
JP6817962B2
(ja)
|
2015-01-20 |
2021-01-20 |
アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． |
ターゲティングされたアンドロゲン受容体分解のための化合物および方法
|
|
US12312316B2
(en)
|
2015-01-20 |
2025-05-27 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
WO2016197114A1
(en)
|
2015-06-05 |
2016-12-08 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
|
WO2017011371A1
(en)
|
2015-07-10 |
2017-01-19 |
Arvinas, Inc |
Mdm2-based modulators of proteolysis and associated methods of use
|
|
EP3337476A4
(en)
|
2015-08-19 |
2019-09-04 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
US11395820B2
(en)
|
2016-03-16 |
2022-07-26 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Small molecules against cereblon to enhance effector t cell function
|
|
US20170281784A1
(en)
|
2016-04-05 |
2017-10-05 |
Arvinas, Inc. |
Protein-protein interaction inducing technology
|
|
EP3454862B1
(en)
|
2016-05-10 |
2024-09-11 |
C4 Therapeutics, Inc. |
Spirocyclic degronimers for target protein degradation
|
|
EP4491236A3
(en)
|
2016-05-10 |
2025-04-02 |
C4 Therapeutics, Inc. |
Heterocyclic degronimers for target protein degradation
|
|
CN109641874A
(zh)
|
2016-05-10 |
2019-04-16 |
C4医药公司 |
用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
|
|
CN109790143A
(zh)
|
2016-05-10 |
2019-05-21 |
C4医药公司 |
用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
|
|
PT3500299T
(pt)
|
2016-08-19 |
2024-02-21 |
Beigene Switzerland Gmbh |
Combinação de zanubrutinib com um anticorpo anti-cd20 ou anti-pd-1 para utilização no tratamento do cancro
|
|
WO2018053354A1
(en)
|
2016-09-15 |
2018-03-22 |
Arvinas, Inc. |
Indole derivatives as estrogen receptor degraders
|
|
WO2018071606A1
(en)
|
2016-10-11 |
2018-04-19 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
IL290809B2
(en)
|
2016-11-01 |
2024-01-01 |
Arvinas Operations Inc |
Tau-protein targeting protacs and associated methods of use
|
|
KR102674902B1
(ko)
|
2016-12-01 |
2024-06-14 |
아비나스 오퍼레이션스, 인코포레이티드 |
에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체
|
|
US11173211B2
(en)
|
2016-12-23 |
2021-11-16 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
|
|
US10806737B2
(en)
|
2016-12-23 |
2020-10-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
|
|
CN117510491A
(zh)
|
2016-12-23 |
2024-02-06 |
阿尔维纳斯运营股份有限公司 |
用于迅速加速性纤维肉瘤多肽的靶向降解的化合物和方法
|
|
MX2019007646A
(es)
|
2016-12-23 |
2019-09-06 |
Arvinas Operations Inc |
Moleculas quimericas dirigidas a la proteolisis del egfr y metodos asociados de uso.
|
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
|
AU2018211975B2
(en)
|
2017-01-26 |
2022-05-26 |
Arvinas Operations, Inc. |
Modulators of estrogen receptor proteolysis and associated methods of use
|
|
BR112019015484A2
(pt)
|
2017-01-31 |
2020-04-28 |
Arvinas Operations Inc |
ligantes de cereblon e compostos bifuncionais compreendendo os mesmos
|
|
EP4717317A2
(en)
|
2017-06-20 |
2026-04-01 |
C4 Therapeutics, Inc. |
N/o-linked degrons and degronimers for protein degradation
|
|
TW202515616A
(zh)
|
2017-06-26 |
2025-04-16 |
英屬開曼群島商百濟神州有限公司 |
抗pd-1抗體或其抗原結合片段在製備治療用於患有肝細胞癌(hcc)之藥物的用途
|
|
TWI791552B
(zh)
|
2017-07-10 |
2023-02-11 |
美商西建公司 |
抗增生化合物及其使用方法
|
|
TWI793151B
(zh)
|
2017-08-23 |
2023-02-21 |
瑞士商諾華公司 |
3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
|
|
CN118108706A
(zh)
|
2017-09-04 |
2024-05-31 |
C4医药公司 |
戊二酰亚胺
|
|
CN118206529A
(zh)
|
2017-09-04 |
2024-06-18 |
C4医药公司 |
二氢苯并咪唑酮
|
|
CN111278816B
(zh)
|
2017-09-04 |
2024-03-15 |
C4医药公司 |
二氢喹啉酮
|
|
EP3710002A4
(en)
|
2017-11-16 |
2021-07-07 |
C4 Therapeutics, Inc. |
DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION
|
|
US11065231B2
(en)
|
2017-11-17 |
2021-07-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
|
|
CN111801334B
(zh)
|
2017-11-29 |
2023-06-09 |
百济神州瑞士有限责任公司 |
使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
|
|
US11220515B2
(en)
|
2018-01-26 |
2022-01-11 |
Yale University |
Imide-based modulators of proteolysis and associated methods of use
|
|
US11028088B2
(en)
|
2018-03-10 |
2021-06-08 |
Yale University |
Modulators of BTK proteolysis and methods of use
|
|
EP3774804A1
(en)
|
2018-03-26 |
2021-02-17 |
Novartis AG |
N-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives
|
|
JP2021519337A
(ja)
|
2018-03-26 |
2021-08-10 |
シー４ セラピューティクス， インコーポレイテッド |
Ｉｋａｒｏｓの分解のためのセレブロン結合剤
|
|
US12539292B2
(en)
|
2018-04-01 |
2026-02-03 |
Arvinas Operations, Inc. |
BRM targeting compounds and associated methods of use
|
|
KR20210006356A
(ko)
|
2018-04-04 |
2021-01-18 |
아비나스 오퍼레이션스, 인코포레이티드 |
단백질분해 조절제 및 연관된 사용 방법
|
|
CN110357889B
(zh)
*
|
2018-04-09 |
2022-03-15 |
上海科技大学 |
蛋白降解靶向化合物、其抗肿瘤应用、其中间体及中间体应用
|
|
CA3095912A1
(en)
*
|
2018-04-13 |
2019-10-17 |
Arvinas Operations, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
CN119751456A
(zh)
|
2018-04-16 |
2025-04-04 |
C4医药公司 |
螺环化合物
|
|
CN118344338A
(zh)
|
2018-04-23 |
2024-07-16 |
细胞基因公司 |
取代的4-氨基异吲哚啉-1,3-二酮化合物以及它们用于治疗淋巴瘤的用途
|
|
WO2019222272A1
(en)
|
2018-05-14 |
2019-11-21 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
EP3578561A1
(en)
|
2018-06-04 |
2019-12-11 |
F. Hoffmann-La Roche AG |
Spiro compounds
|
|
DK3820573T3
(da)
|
2018-07-10 |
2023-10-23 |
Novartis Ag |
3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidin-2,6-dion-derivativer og anvendelse deraf ved behandling af ikaros family zinc finger 2 (ikzf2)-afhængige sygdomme
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
BR112021000395A2
(pt)
|
2018-07-11 |
2021-04-06 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Compostos imunomoduladores diméricos contra mecanismos baseados em cereblon
|
|
US20200038513A1
(en)
|
2018-07-26 |
2020-02-06 |
Arvinas Operations, Inc. |
Modulators of fak proteolysis and associated methods of use
|
|
WO2020027225A1
(ja)
|
2018-07-31 |
2020-02-06 |
ファイメクス株式会社 |
複素環化合物
|
|
EP3841100A1
(en)
|
2018-08-20 |
2021-06-30 |
Arvinas Operations, Inc. |
Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases
|
|
US11969472B2
(en)
|
2018-08-22 |
2024-04-30 |
Cullgen (Shanghai), Inc. |
Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
|
|
MX2021001957A
(es)
|
2018-08-22 |
2021-07-15 |
Cullgen Shanghai Inc |
Compuestos de degradacion y metodos de uso del receptor de tropomiosina quinasa (trk).
|
|
WO2020051235A1
(en)
|
2018-09-04 |
2020-03-12 |
C4 Therapeutics, Inc. |
Compounds for the degradation of brd9 or mth1
|
|
JP2022507267A
(ja)
*
|
2018-11-13 |
2022-01-18 |
バイオセリックス， インコーポレイテッド |
置換イソインドリノン
|
|
JP7623943B2
(ja)
|
2018-11-30 |
2025-01-29 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋ分解剤およびそれらの使用
|
|
US11325889B2
(en)
|
2018-12-19 |
2022-05-10 |
Celgene Corporation |
Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
|
|
PL3897636T3
(pl)
|
2018-12-19 |
2025-04-28 |
Celgene Corporation |
Podstawione związki 3-((3-aminofenylo)amino)piperydyno-2,6-dionu, ich kompozycje i sposoby leczenia nimi
|
|
CN120698983A
(zh)
|
2018-12-20 |
2025-09-26 |
C4医药公司 |
靶向蛋白降解
|
|
WO2020142228A1
(en)
*
|
2019-01-03 |
2020-07-09 |
The Regents Of The University Of Michigan |
Androgen receptor protein degraders
|
|
WO2020160193A2
(en)
*
|
2019-01-29 |
2020-08-06 |
Foghorn Therapeutics Inc. |
Compounds and uses thereof
|
|
CN113874016A
(zh)
|
2019-01-29 |
2021-12-31 |
福宏治疗公司 |
化合物及其用途
|
|
JP7555938B2
(ja)
*
|
2019-01-30 |
2024-09-25 |
モンテリノ・セラピューティクス・インコーポレイテッド |
アンドロゲン受容体を標的とするユビキチン化のための二官能性化合物および方法
|
|
US11547759B2
(en)
|
2019-01-30 |
2023-01-10 |
Montelino Therapeutics, Inc. |
Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
|
|
EP3924055B1
(en)
*
|
2019-02-15 |
2024-04-03 |
Novartis AG |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
CN113490528B
(zh)
*
|
2019-02-15 |
2024-12-03 |
诺华股份有限公司 |
3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
|
|
EP3932922A4
(en)
*
|
2019-02-25 |
2022-05-11 |
ShanghaiTech University |
SULPHUR-CONTAINING COMPOUND BASED ON A GLUTARIMIDE FRAMEWORK AND ITS USE
|
|
CA3132446A1
(en)
*
|
2019-03-05 |
2020-09-10 |
Centre For Addiction And Mental Health |
Modulators of ampa receptor signaling
|
|
WO2020181232A1
(en)
|
2019-03-06 |
2020-09-10 |
C4 Therapeutics, Inc. |
Heterocyclic compounds for medical treatment
|
|
WO2020191369A1
(en)
|
2019-03-21 |
2020-09-24 |
Codiak Biosciences, Inc. |
Process for preparing extracellular vesicles
|
|
KR20210141554A
(ko)
|
2019-03-21 |
2021-11-23 |
코디악 바이오사이언시즈, 인크. |
세포외 소포 접합체 및 이의 용도
|
|
CN111747924B
(zh)
*
|
2019-03-29 |
2023-11-10 |
华东师范大学 |
一类来那度胺/泊马度胺类似物及其应用
|
|
TW202102497A
(zh)
|
2019-03-29 |
2021-01-16 |
瑞典商阿斯特捷利康公司 |
化合物及它們在治療癌症中之用途
|
|
US12414995B2
(en)
|
2019-04-16 |
2025-09-16 |
Northwestern University |
Bifunctional compounds comprising Apcin-A and their use in the treatment of cancer
|
|
KR20220004100A
(ko)
*
|
2019-04-18 |
2022-01-11 |
하이노바 파마슈티컬스 인코포레이티드 |
안드로겐 수용체를 표적 분해하는 이중 기능성의 키메라 헤테로 고리 화합물 및 이의 용도
|
|
CN113811333B
(zh)
|
2019-05-14 |
2024-03-12 |
诺维逊生物股份有限公司 |
靶向抗癌核激素受体的化合物
|
|
JP2022533147A
(ja)
*
|
2019-05-17 |
2022-07-21 |
ヒノバ ファーマシューティカルズ インコーポレイテッド |
芳香族アミン類のａｒ及びｂｅｔを標的とするタンパク質分解キメラ化合物及び使用
|
|
WO2020243423A1
(en)
|
2019-05-31 |
2020-12-03 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
TWI762939B
(zh)
|
2019-05-31 |
2022-05-01 |
大陸商海思科醫藥集團股份有限公司 |
Btk抑制劑環衍生物及其製備方法和藥學上的應用
|
|
KR20220030222A
(ko)
|
2019-05-31 |
2022-03-10 |
이케나 온콜로지, 인코포레이티드 |
Tead 억제제 및 이의 용도
|
|
BR112021026517A2
(pt)
|
2019-06-28 |
2022-05-10 |
Kymera Therapeutics Inc |
Degradadores de irak e usos dos mesmos
|
|
CN119954801A
(zh)
|
2019-07-17 |
2025-05-09 |
阿尔维纳斯运营股份有限公司 |
Tau蛋白靶向化合物及相关使用方法
|
|
WO2021011868A1
(en)
|
2019-07-17 |
2021-01-21 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
WO2021022163A2
(en)
|
2019-07-31 |
2021-02-04 |
Foghorn Therapeutics Inc. |
Compounds and uses thereof
|
|
WO2021023233A1
(zh)
|
2019-08-05 |
2021-02-11 |
上海科技大学 |
Egfr蛋白降解剂及其抗肿瘤应用
|
|
IL320609A
(en)
|
2019-08-26 |
2025-07-01 |
Arvinas Operations Inc |
Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents
|
|
JP7785663B2
(ja)
*
|
2019-09-16 |
2025-12-15 |
ノバルティス アーゲー |
二機能性分解誘導薬及びそれらの使用方法
|
|
US20220380368A1
(en)
*
|
2019-09-19 |
2022-12-01 |
The Regents Of The University Of Michigan |
Spirocyclic androgen receptor protein degraders
|
|
JP2022549222A
(ja)
*
|
2019-09-23 |
2022-11-24 |
アキュター バイオテクノロジー インコーポレイテッド |
アンドロゲン受容体分解活性を有する新規尿素およびその使用
|
|
US10836749B1
(en)
|
2019-09-23 |
2020-11-17 |
Accutar Biotechnology Inc. |
Substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof
|
|
EP4041231A1
(en)
*
|
2019-10-09 |
2022-08-17 |
Monte Rosa Therapeutics AG |
Isoindolinone compounds
|
|
CN115397821B
(zh)
|
2019-10-17 |
2024-09-03 |
阿尔维纳斯运营股份有限公司 |
含有与bcl6靶向部分连接的e3泛素连接酶结合部分的双官能分子
|
|
JP7716396B2
(ja)
*
|
2019-10-22 |
2025-07-31 |
アルビナス・オペレーションズ・インコーポレイテッド |
前立腺癌を治療する方法
|
|
CN110790750B
(zh)
*
|
2019-11-07 |
2021-09-21 |
郑州大学 |
一种邻苯二甲酰亚胺类选择性雄激素受体降解剂及其制备方法和用途
|
|
CN110746400B
(zh)
*
|
2019-11-07 |
2021-12-17 |
郑州大学 |
一种靶向雄激素受体的荧光探针及其制备方法
|
|
WO2021097046A1
(en)
|
2019-11-13 |
2021-05-20 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
AU2020387392B2
(en)
|
2019-11-19 |
2025-09-11 |
Bristol-Myers Squibb Company |
Compounds useful as inhibitors of Helios protein
|
|
US12551564B2
(en)
|
2019-12-10 |
2026-02-17 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
|
JP2023507590A
(ja)
*
|
2019-12-17 |
2023-02-24 |
オリオニス バイオサイエンシズ，インコーポレイテッド |
タンパク質の動員および／または分解を調節する化合物
|
|
WO2021127190A1
(en)
|
2019-12-17 |
2021-06-24 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
JP7682181B2
(ja)
|
2019-12-18 |
2025-05-23 |
ノバルティス アーゲー |
３－（５－メトキシ－１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
|
|
CA3165168A1
(en)
*
|
2019-12-19 |
2021-06-24 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
CA3162523A1
(en)
|
2019-12-23 |
2021-07-01 |
Hongfu LU |
Protein degradation agent compound preparation method and application
|
|
US12528825B2
(en)
|
2020-01-29 |
2026-01-20 |
Foghorn Therapeutics Inc. |
Compounds and uses thereof
|
|
EP4107158A1
(en)
|
2020-02-19 |
2022-12-28 |
Nurix Therapeutics, Inc. |
Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof
|
|
WO2023205701A1
(en)
|
2022-04-20 |
2023-10-26 |
Kumquat Biosciences Inc. |
Macrocyclic heterocycles and uses thereof
|
|
CA3169011A1
(en)
*
|
2020-02-25 |
2021-09-02 |
Xiaobao Yang |
Glutarimide skeleton-based compounds and uses thereof
|
|
CA3173262A1
(en)
|
2020-02-26 |
2021-09-02 |
Cullgen (Shanghai), Inc. |
Tropomyosin receptor kinase (trk) degradation compounds and methods of use
|
|
AU2021231898A1
(en)
|
2020-03-05 |
2022-10-27 |
C4 Therapeutics, Inc. |
Compounds for targeted degradation of BRD9
|
|
CN113387930B
(zh)
*
|
2020-03-11 |
2022-07-12 |
苏州开拓药业股份有限公司 |
一种双官能化合物及其制备方法和用途
|
|
TW202140441A
(zh)
|
2020-03-23 |
2021-11-01 |
美商必治妥美雅史谷比公司 |
經取代之側氧基異吲哚啉化合物
|
|
CN113582974B
(zh)
*
|
2020-04-30 |
2022-05-17 |
江西济民可信集团有限公司 |
一类作为蛋白降解剂的化合物及其制备方法和医药用途
|
|
CN115996918A
(zh)
|
2020-05-09 |
2023-04-21 |
阿尔维纳斯运营股份有限公司 |
制造双官能团化合物的方法、双官能团化合物的超纯形式以及包括所述双官能团化合物的剂型
|
|
JP2023526055A
(ja)
*
|
2020-05-12 |
2023-06-20 |
アルビナス・オペレーションズ・インコーポレイテッド |
前立腺癌を治療する方法
|
|
US20230357249A1
(en)
*
|
2020-05-14 |
2023-11-09 |
The Regents Of The University Of Michigan |
Androgen receptor protein degraders with a tricyclic cereblon ligand
|
|
WO2021237100A1
(en)
|
2020-05-21 |
2021-11-25 |
Codiak Biosciences, Inc. |
Methods of targeting extracellular vesicles to lung
|
|
CN113801098B
(zh)
|
2020-06-12 |
2023-05-30 |
上海济煜医药科技有限公司 |
酞嗪酮类化合物及其制备方法和医药用途
|
|
WO2021255212A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Braf degraders
|
|
CN113896711A
(zh)
*
|
2020-07-06 |
2022-01-07 |
北京诺诚健华医药科技有限公司 |
杂环类免疫调节剂
|
|
US20230233690A1
(en)
*
|
2020-07-10 |
2023-07-27 |
The Regents Of The University Of Michigan |
Androgen receptor protein degraders
|
|
US20230257365A1
(en)
*
|
2020-07-10 |
2023-08-17 |
The Regents Of The University Of Michigan |
Small molecule androgen receptor protein degraders
|
|
WO2022019597A1
(ko)
*
|
2020-07-21 |
2022-01-27 |
주식회사 유빅스테라퓨틱스 |
안드로겐 수용체 분해용 화합물 및 이들의 의약 용도
|
|
JP2023542608A
(ja)
*
|
2020-08-04 |
2023-10-11 |
オリック ファーマシューティカルズ，インク． |
グルココルチコイド受容体（ｇｒ）アンタゴニストおよびアンドロゲン受容体（ａｒ）分解誘導剤の組み合わせの使用
|
|
EP4192458A4
(en)
|
2020-08-05 |
2024-09-04 |
C4 Therapeutics, Inc. |
COMPOUNDS FOR TARGETED DEGRADATION OF RET
|
|
JP7834721B2
(ja)
|
2020-08-28 |
2026-03-24 |
アルビナス・オペレーションズ・インコーポレイテッド |
急速進行性線維肉腫タンパク質分解化合物及び関連する使用方法
|
|
WO2022048605A1
(zh)
*
|
2020-09-04 |
2022-03-10 |
南昌奥瑞药业有限公司 |
一种杂环化合物、其制备方法、中间体、组合物以及应用
|
|
CN114163444B
(zh)
*
|
2020-09-11 |
2023-07-14 |
江苏恒瑞医药股份有限公司 |
一种用于雄激素受体蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用
|
|
CN114181196A
(zh)
*
|
2020-09-14 |
2022-03-15 |
海思科医药集团股份有限公司 |
一种抑制并降解parp酶的化合物及其制备方法和药学上的应用
|
|
AR123492A1
(es)
|
2020-09-14 |
2022-12-07 |
Arvinas Operations Inc |
Formas cristalinas y amorfas de un compuesto para la degradación dirigida del receptor de estrógeno
|
|
CN114181277A
(zh)
*
|
2020-09-15 |
2022-03-15 |
江苏恒瑞医药股份有限公司 |
一种用于雄激素受体蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用
|
|
US20240241020A1
(en)
|
2020-09-23 |
2024-07-18 |
Lonza Sales Ag |
Process for preparing extracellular vesicles
|
|
WO2022066835A1
(en)
|
2020-09-23 |
2022-03-31 |
St. Jude Children's Research Hospital, Inc. |
Substituted n-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)arylsulfonamide analogs as modulators of cereblon protein
|
|
AU2021365850A1
(en)
*
|
2020-10-21 |
2023-06-08 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor protein
|
|
EP4240733A1
(en)
*
|
2020-11-06 |
2023-09-13 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor and associated methods of use
|
|
WO2022099117A1
(en)
|
2020-11-06 |
2022-05-12 |
Prelude Therapeutics Incorporated |
Brm targeting compounds and associated methods of use
|
|
CN116529248B
(zh)
*
|
2020-11-25 |
2025-10-17 |
西藏海思科制药有限公司 |
一种苯环衍生物及其组合物和药学上的应用
|
|
CN114262319B
(zh)
*
|
2020-12-01 |
2023-05-05 |
南昌奥瑞药业有限公司 |
一类双功能分子、其制备方法及其应用
|
|
WO2022120355A1
(en)
*
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead degraders and uses thereof
|
|
KR20230118147A
(ko)
|
2020-12-11 |
2023-08-10 |
아비나스 오퍼레이션스, 인코포레이티드 |
전립선암 치료 방법
|
|
EP4023649A1
(en)
|
2020-12-30 |
2022-07-06 |
Industrial Technology Research Institute |
Androgen receptor binding bifunctional molecules
|
|
JP2024504932A
(ja)
|
2021-01-13 |
2024-02-02 |
モンテ ローザ セラピューティクス， インコーポレイテッド |
イソインドリノン化合物
|
|
US20240165243A1
(en)
|
2021-02-10 |
2024-05-23 |
Beigene Switzerland Gmbh |
Egfr degraders and methods of use
|
|
CN116867494A
(zh)
|
2021-02-15 |
2023-10-10 |
凯麦拉医疗公司 |
Irak4降解剂和其用途
|
|
WO2022174268A1
(en)
|
2021-02-15 |
2022-08-18 |
Kymera Therapeutics, Inc. |
Irak4 degraders and uses thereof
|
|
WO2022187423A1
(en)
*
|
2021-03-03 |
2022-09-09 |
The Regents Of The University Of Michigan |
Cereblon ligands
|
|
WO2022187419A1
(en)
*
|
2021-03-03 |
2022-09-09 |
The Regents Of The University Of Michigan |
Small molecule degraders of androgen receptor
|
|
TWI807697B
(zh)
*
|
2021-03-17 |
2023-07-01 |
大陸商南京明德新藥研發有限公司 |
呋喃稠環取代的戊二醯亞胺類化合物
|
|
WO2022198112A1
(en)
*
|
2021-03-19 |
2022-09-22 |
Arvinas Operations, Inc. |
Indazole based compounds and associated methods of use
|
|
KR20230160299A
(ko)
|
2021-03-23 |
2023-11-23 |
누베이션 바이오 인크. |
항암 핵 호르몬 수용체 표적화 화합물
|
|
BR112023020077A2
(pt)
|
2021-04-06 |
2023-11-14 |
Bristol Myers Squibb Co |
Compostos de oxoisoindolina substituída por piridinila
|
|
CN117279910A
(zh)
|
2021-04-16 |
2023-12-22 |
阿尔维纳斯运营股份有限公司 |
Bcl6蛋白水解的调节剂和其相关使用方法
|
|
CA3209633A1
(en)
*
|
2021-04-29 |
2022-11-03 |
Tinghu Zhang |
Phthalimido cereblon complex binders and transcription factor degraders and methods of use
|
|
US12006314B2
(en)
|
2021-05-03 |
2024-06-11 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
KR20240017814A
(ko)
|
2021-05-05 |
2024-02-08 |
바이오젠 엠에이 인코포레이티드 |
브루톤 티로신 키나제의 분해를 표적으로 하는 화합물
|
|
AU2022271290A1
(en)
|
2021-05-07 |
2023-11-23 |
Kymera Therapeutics, Inc. |
Cdk2 degraders and uses thereof
|
|
WO2022251588A1
(en)
*
|
2021-05-27 |
2022-12-01 |
Halda Therapeutics Opco, Inc. |
Heterobifunctional compounds and methods of treating disease
|
|
WO2022255888A1
(en)
*
|
2021-06-01 |
2022-12-08 |
Captor Therapeutics S.A. |
Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein
|
|
PY2243958A
(es)
|
2021-06-03 |
2023-01-20 |
Novartis Ag |
Derivados de 3–(5–oxi)–1–oxoisoindolin–2–il)piperidina–2,6–diona y sus usos
|
|
BR112023025403A2
(pt)
|
2021-06-25 |
2024-02-20 |
Korea Res Inst Chemical Tech |
Composto heterocíclico bifuncional tendo função de degradação de btk por meio da via ubiquitina proteassoma e uso do mesmo
|
|
KR20240035526A
(ko)
|
2021-07-07 |
2024-03-15 |
바이오젠 엠에이 인코포레이티드 |
Irak4 단백질의 분해를 표적하는 화합물
|
|
WO2023283372A1
(en)
|
2021-07-07 |
2023-01-12 |
Biogen Ma Inc. |
Compounds for targeting degradation of irak4 proteins
|
|
KR20240035820A
(ko)
|
2021-07-09 |
2024-03-18 |
플렉시움 인코포레이티드 |
Ikzf2를 조절하는 아릴 화합물 및 약학 조성물
|
|
FI4367118T3
(fi)
|
2021-08-18 |
2025-04-09 |
Nurix Therapeutics Inc |
Interleukiini-1-reseptoriin liittyvien kinaasien bifunktionaalisia hajotusaineita ja niiden terapeuttinen käyttö
|
|
WO2023025268A1
(zh)
*
|
2021-08-27 |
2023-03-02 |
苏州晶云药物科技股份有限公司 |
哒嗪甲酰胺类化合物的晶型及其制备方法
|
|
WO2023034411A1
(en)
|
2021-09-01 |
2023-03-09 |
Oerth Bio Llc |
Compositions and methods for targeted degradation of proteins in a plant cell
|
|
CN115772210A
(zh)
*
|
2021-09-08 |
2023-03-10 |
苏州开拓药业股份有限公司 |
硫代乙内酰脲化合物或其药用盐的无定形物、晶体、药物组合物、制备方法和用途
|
|
CN113861186B
(zh)
*
|
2021-09-10 |
2023-08-25 |
浙江师范大学 |
基于异恶唑取代苯甲酰胺类衍生物及抗前列腺癌药物应用
|
|
US20240382603A1
(en)
*
|
2021-09-13 |
2024-11-21 |
Montelino Therapeutics, Inc. |
Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
|
|
US11981672B2
(en)
|
2021-09-13 |
2024-05-14 |
Montelino Therapeutics Inc. |
Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
|
|
CN113620931B
(zh)
*
|
2021-09-13 |
2023-06-09 |
中国海洋大学 |
一种雄激素受体抑制剂及其用途
|
|
US20240376118A1
(en)
*
|
2021-09-13 |
2024-11-14 |
Montelino Therapeutics, Inc. |
Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
|
|
EP4417965A4
(en)
|
2021-10-15 |
2025-10-29 |
Univ Tsukuba |
INFORMATION PROCESSING DEVICE, INFORMATION PROCESS AND PROGRAM
|
|
AU2022370021B2
(en)
*
|
2021-10-22 |
2026-04-16 |
Gluetacs Therapeutics (Shanghai) Co., Ltd. |
Crbn e3 ligase ligand compound, protein degrading agent developed on the basis of ligand compound, and their applications
|
|
US12187744B2
(en)
|
2021-10-29 |
2025-01-07 |
Kymera Therapeutics, Inc. |
IRAK4 degraders and synthesis thereof
|
|
JP2024543129A
(ja)
*
|
2021-11-25 |
2024-11-19 |
江蘇恒瑞医薬股▲ふん▼有限公司 |
アンドロゲン受容体タンパク質の標的分解のためのキメラ化合物、その調製方法及びその医薬的使用
|
|
CN115894450B
(zh)
*
|
2021-11-30 |
2023-09-12 |
山东如至生物医药科技有限公司 |
一种新型多环类化合物及其组合物和用途
|
|
AU2022405474A1
(en)
*
|
2021-12-08 |
2024-07-18 |
Gluetacs Therapeutics (Shanghai) Co., Ltd. |
E3 ubiquitin ligase ligand compound, protein degrader developed based thereon and their applications
|
|
CN118401512A
(zh)
*
|
2021-12-24 |
2024-07-26 |
苏州开拓药业股份有限公司 |
一种具有酰亚胺骨架的多蛋白降解剂
|
|
AU2022424178A1
(en)
|
2021-12-30 |
2024-07-11 |
Beone Medicines I Gmbh |
Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
|
|
TW202346281A
(zh)
|
2022-01-21 |
2023-12-01 |
瑞典商阿斯特捷利康公司 |
化合物以及它們在治療癌症中之用途
|
|
WO2023143427A1
(zh)
*
|
2022-01-27 |
2023-08-03 |
杭州领业医药科技有限公司 |
Arv-110的晶型及其制备方法和用途
|
|
KR20230140396A
(ko)
|
2022-03-23 |
2023-10-06 |
주식회사 대웅테라퓨틱스 |
핵 수용체의 저해 또는 분해를 유도하는 신규 화합물
|
|
CN119301111A
(zh)
|
2022-03-24 |
2025-01-10 |
葛兰素史密斯克莱知识产权发展有限公司 |
作为protac中的降解决定子的2,4-二氧代四氢嘧啶基衍生物
|
|
CN119604285A
(zh)
|
2022-03-25 |
2025-03-11 |
深圳市药欣生物科技有限公司 |
Protac化合物的药物组合物及其用途
|
|
US20250221988A1
(en)
*
|
2022-04-06 |
2025-07-10 |
Cullgen (Shanghai), Inc. |
Compounds and methods of treating cancers
|
|
TW202404643A
(zh)
|
2022-04-20 |
2024-02-01 |
大陸商同宜醫藥（蘇州）有限公司 |
化合物及用途
|
|
US20250248999A1
(en)
|
2022-04-21 |
2025-08-07 |
Arvinas Operations, Inc. |
Bavdegalutamide and combinations thereof for use in treating prostate cancer
|
|
JP2025523393A
(ja)
|
2022-06-06 |
2025-07-23 |
シーフォー セラピューティクス， インコーポレイテッド |
二環式置換グルタルイミドセレブロンバインダー
|
|
WO2023242598A1
(en)
*
|
2022-06-16 |
2023-12-21 |
Amphista Therapeutics Limited |
Bifunctional molecules for targeted protein degradation
|
|
US20240067632A1
(en)
*
|
2022-06-30 |
2024-02-29 |
Bristol-Myers Squibb Company |
WEE1 Degrading Compounds and Uses Thereof
|
|
AU2023300784A1
(en)
*
|
2022-06-30 |
2025-01-02 |
Anhorn Medicines Co., Ltd. |
Bifunctional compound and pharmaceutical composition comprising the bifunctional compound, and method for treating androgen receptor related diseases by using the same
|
|
CN119948021A
(zh)
*
|
2022-07-15 |
2025-05-06 |
西藏海思科制药有限公司 |
一种含氮杂环衍生物及其组合物和药学上的应用
|
|
CN119698271A
(zh)
*
|
2022-07-20 |
2025-03-25 |
加利福尼亚大学董事会 |
含有达罗他胺的药物植入物及其使用方法
|
|
CN115475164B
(zh)
*
|
2022-08-22 |
2024-06-04 |
西安交通大学 |
一种可降解PDGFR-β的蛋白降解靶向嵌合体及其制备方法和应用
|
|
WO2024050016A1
(en)
|
2022-08-31 |
2024-03-07 |
Oerth Bio Llc |
Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
|
|
EP4584258A1
(en)
|
2022-09-07 |
2025-07-16 |
Arvinas Operations, Inc. |
Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
|
|
WO2024054952A1
(en)
*
|
2022-09-08 |
2024-03-14 |
Halda Therapeutics Opco, Inc. |
Heterobifunctional compounds and methods of treating disease
|
|
WO2024054954A1
(en)
*
|
2022-09-08 |
2024-03-14 |
Halda Therapeutics Opco, Inc. |
Heterobifunctional compounds and methods of treating disease
|
|
TWI853707B
(zh)
*
|
2022-09-14 |
2024-08-21 |
大陸商上海齊魯製藥研究中心有限公司 |
萘并呋喃取代的戊二醯亞胺類化合物的晶型、製備方法及其應用
|
|
WO2024073507A1
(en)
|
2022-09-28 |
2024-04-04 |
Theseus Pharmaceuticals, Inc. |
Macrocyclic compounds and uses thereof
|
|
US20240207415A1
(en)
|
2022-11-08 |
2024-06-27 |
Montelino Therapeutics, Inc. |
Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
|
|
WO2024126617A1
(en)
|
2022-12-14 |
2024-06-20 |
Crossfire Oncology Holding B.V. |
Bifunctional compounds for degrading kinases via ubiquitin proteosome pathway
|
|
CN121419983A
(zh)
|
2023-01-26 |
2026-01-27 |
阿尔维纳斯运营股份有限公司 |
基于小脑蛋白的kras降解protac及其相关用途
|
|
AU2024235906A1
(en)
|
2023-03-10 |
2025-10-30 |
Astrazeneca Ab |
Bifunctional compounds capable of degrading androgen receptors
|
|
WO2024201244A1
(en)
|
2023-03-24 |
2024-10-03 |
Assia Chemical Industries Ltd. |
Solid state forms of bavdegalutamide and process for preparation thereof
|
|
WO2024220926A1
(en)
|
2023-04-21 |
2024-10-24 |
Arvinas Operations, Inc. |
Use of an androgen receptor degrader protac for the treatment of prostate cancer
|
|
WO2024233696A1
(en)
|
2023-05-09 |
2024-11-14 |
Arvinas Operations, Inc. |
Bavdegalutamide for treating prostate cancer without ar l702h mutation
|
|
CN120981456A
(zh)
|
2023-05-24 |
2025-11-18 |
金橘生物科技公司 |
杂环化合物及其用途
|
|
AU2024278036A1
(en)
|
2023-05-24 |
2025-11-27 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Amorphous substance and crystal of dioxopiperidine compound or pharmaceutically acceptable salt thereof, preparation method, and use
|
|
AU2024281173A1
(en)
|
2023-05-31 |
2025-12-04 |
Beone Medicines I Gmbh |
Compounds for the degradation of egfr kinase
|
|
AU2024307234A1
(en)
|
2023-06-30 |
2026-01-29 |
Kumquat Biosciences Inc. |
Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors
|
|
WO2025011623A1
(zh)
*
|
2023-07-12 |
2025-01-16 |
上海壹迪生物技术有限公司 |
氰基喹啉类靶向蛋白降解分子、其制备方法和应用
|
|
CN117263865B
(zh)
*
|
2023-08-04 |
2026-03-27 |
南开大学 |
以6,6-二甲基双环[3.1.1]-2-甲胺为疏水基团的蛋白降解剂及其制备方法、药物组合物和应用
|
|
CN117126133A
(zh)
*
|
2023-08-14 |
2023-11-28 |
中国海洋大学 |
一种化合物及其用途
|
|
WO2025049555A1
(en)
|
2023-08-31 |
2025-03-06 |
Oerth Bio Llc |
Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
|
|
AU2024352092A1
(en)
|
2023-09-28 |
2026-04-09 |
Arvinas Operations, Inc. |
Benzimidazole and benzimidazolone based protac compounds for the targeted degradation of leucine rich repeat kinase 2 (lrrk2)
|
|
WO2025085815A1
(en)
*
|
2023-10-20 |
2025-04-24 |
Seed Therapeutics Us, Inc. |
Protac compounds binding keap1 ubiquitin ligase for targeted protein degradation
|
|
WO2025083472A2
(en)
*
|
2023-10-20 |
2025-04-24 |
Seed Therapeutics Us, Inc. |
Protac compounds binding keap1 ubiquitin ligase for targeted protein degradation
|
|
WO2025096855A1
(en)
|
2023-11-02 |
2025-05-08 |
Kumquat Biosciences Inc. |
Degraders and uses thereof
|
|
CN120025326A
(zh)
*
|
2023-11-22 |
2025-05-23 |
广东东阳光药业股份有限公司 |
一种靶向降解雄激素受体的双功能嵌合体的杂环化合物及其用途
|
|
US20250177539A1
(en)
|
2023-12-01 |
2025-06-05 |
Astrazeneca Ab |
Er degraders and uses thereof
|
|
US12496301B2
(en)
|
2023-12-08 |
2025-12-16 |
Arvinas Operations, Inc. |
Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy
|
|
WO2025126115A1
(en)
|
2023-12-13 |
2025-06-19 |
Beigene Switzerland Gmbh |
Degradation of irak4 by conjugation of irak4 inhibitors with e3 ligase ligands and methods of use
|
|
WO2025152777A1
(zh)
*
|
2024-01-18 |
2025-07-24 |
海创药业股份有限公司 |
一种制备雄激素受体靶向降解化合物及其盐的方法
|
|
TW202543650A
(zh)
|
2024-03-08 |
2025-11-16 |
美商海爾達醫療運營公司 |
異雙官能化合物及其在治療疾病中之用途
|
|
CN118084737A
(zh)
*
|
2024-04-07 |
2024-05-28 |
江苏工程职业技术学院 |
4-(1-((叔丁氧基羰基)氨基)环丁基)苯甲酸的合成方法
|
|
WO2025226797A1
(en)
*
|
2024-04-24 |
2025-10-30 |
Genentech, Inc. |
Kred catalyzed ketoreduction of a cyclobutanone carbamic ester
|
|
US20250346577A1
(en)
*
|
2024-05-07 |
2025-11-13 |
Bristol-Myers Squibb Company |
Processes for the preparation of substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds
|
|
CN118955474A
(zh)
*
|
2024-07-29 |
2024-11-15 |
浙江爱索拓标记医药科技有限公司 |
一种放射性同位素碳-14标记的巴德卡鲁胺及其制备方法和应用
|
|
CN121735910A
(zh)
*
|
2024-09-27 |
2026-03-27 |
上海交通大学 |
一种模块化的分子胶化合物库及其构建方法和应用
|